
Loading, please wait...

Loading, please wait...

The Hepatitis burden in India remains a significant public health threat. According to the WHO Global Hepatitis Report 2026, the world is struggling to meet the 2030 elimination targets. Specifically, India ranks as one of the hardest-hit nations globally. Furthermore, viral hepatitis caused over 1.3 million deaths in 2024. Most of these fatalities resulted from Hepatitis B and C infections. These \"silent\" viruses often lead to cirrhosis and liver cancer if left untreated.
India accounts for a massive portion of the global disease load. Consequently, the country contributes to nearly 69% of global Hepatitis B deaths. It also represents 58% of global Hepatitis C deaths. Currently, India has the second-largest Hepatitis C burden, trailing only Pakistan. Estimates suggest around 40 million people live with chronic Hepatitis B in the country. Therefore, prevalence stays high at approximately 2% to 4% among the population.
Medical experts emphasize that the primary challenge is under-diagnosis rather than treatment access. Many patients remain unaware of their status for decades. Moreover, gaps in vaccination coverage and unsafe medical practices persist. Routine screening for pregnant women is often missed, leading to mother-to-child transmission. While Hepatitis C treatment is free and effective, long-term compliance remains weak. Thus, eliminating the virus by 2030 appears increasingly unlikely at the current pace.
Globally, only 5% of Hepatitis B patients receive necessary therapy. Similarly, only 20% of eligible Hepatitis C patients have accessed treatment. Hepatitis B infections often occur during early childhood. In contrast, Hepatitis C spreads primarily through unsafe blood exposure and needle sharing. To improve outcomes, clinicians must scale up screening and safer medical practices. Finally, public awareness campaigns are essential to boost routine testing rates across the nation.
Q1: What are the primary causes of the high hepatitis burden in India?
The high burden stems from gaps in vaccination, under-diagnosis, and unsafe exposures such as needle sharing or razor reuse. Mother-to-child transmission also plays a significant role in Hepatitis B prevalence.
Q2: Why is the 2030 elimination target at risk?
Progress is too slow because of low screening rates and limited treatment access. Despite the availability of affordable drugs, many people remain undiagnosed until the disease reaches advanced stages like cirrhosis.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


India faces a high viral hepatitis burden with millions infected. WHO's 2026 report warns of missing 2030 elimination targets without better diagnosis....
5 months ago

Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today

Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today

In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today

This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today

A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today